In March 2017, PharmOptima, LLC, became part of the New Jersey based Genesis Biotechnology Group. PharmaOptima had functioned as an independent contract research organization, providing consulting and laboratory services. Enabling drug discovery by optimizing drug lead identification utilizing compound biochemical mechanisms of action and proof of concept studies, the firm's drug discovery services offers evaluation of compounds in in-vivo pharmacokinetics (PK) studies in various species, such as mouse, rat, and rabbit. The company also provides bioavailability studies; single dose and multiple dose PK studies in mouse and rat; discovery liquid formulation development and optimization; cassette PK for early discovery compound screening and decision prioritization; drug distribution in tissue/organ and body fluid and determination of blood and brain ratio for brain penetration; organ perfusion; metabolic kinetics with active metabolites; PK study for pharmaceutical formulation and form evaluation, and design of dose and dose regimen in various rodent disease models; and PK modeling and simulation. In addition, it offers services in the areas of in-vivo, biochemistry, bio analytical, ophthalmic, and spinal muscular atrophy; and in-vitro metabolism assessment and pharmacokinetics analysis
